Authors: <\/strong><\/p>\n Miriam Schulze <\/strong>CEO of BAYOOMED<\/p>\n Julia Schliesch <\/strong>Marketing Generalist at BAYOOMED<\/p>\n<\/div> The development of a digital therapeutic (DTx) is much more complex than many initially assume. Between the initial product idea and successful market access, there are numerous regulatory, technical and strategic challenges that need to be considered at an early stage. If you take an unstructured approach here, you risk delays, high costs or even the failure of the entire project.<\/p>\n This is exactly where our compact “From Zero to DTx” checklist<\/strong> comes in. It supports you in setting up DTx development<\/strong> in a structured and targeted manner right from the start. Step by step, it covers all relevant areas – from regulatory requirements and quality management to software architecture, cybersecurity, data protection, clinical evidence and reimbursement strategy.<\/p>\n The checklist not only helps you to maintain an overview, but also to identify critical gaps at an early stage. After all, topics such as MDR compliance, clinical evaluation or market access are what distinguish successful DTx products from those that never make it to approval.<\/p>\n<\/div> which regulatory requirements you must observe<\/p>\n<\/div><\/li> how to set up your product and system architecture sensibly<\/p>\n<\/div><\/li> what role clinical studies and health economics play<\/p>\n<\/div><\/li> and how to successfully place your DTx on the market<\/p>\n<\/div><\/li><\/ul> Whether you are still in the idea phase or already working on an MVP – the checklist gives you a clear orientation and helps you to make informed decisions.<\/p>\n Find out more now:<\/strong>
\nSign up to our contact form and download the complete checklist.<\/p>\n<\/div><\/div><\/div><\/div><\/div>